Human papillomavirus (HPV) infections, especially those affecting the genital mucosae, are associated with significant morbidity and mortality. It is now clear from epidemiological and laboratory studies that infection with specific human papillomavirus (HPV) types, in particular HPV 16 and 18 and their relatives, is the major risk factor for the subsequent development of cervix cancer in women (1). HPV DNA is found in more than 90% of all cervix cancers (13) and some reports suggest that all cervix cancers are HPV associated (28) . Cervical cancer is the second commonest cancer in women worldwide; in developing countries it is the commonest female cancer and has a high mortality rate. Immunological intervention by prophylactic vaccination is an attractive prospect and an effective immunisation strategy against these viruses would be a major development in health care for women, especially in the third world, with a significant effect in reducing health care costs in both the developed and undeveloped world.
The extreme species specificity of the papillomaviruses together with the inability to generate usable amounts of infectious genital HPVs by in vitro culture has meant that animal models are essential for the development and testing of vaccines and anti-virals against these agents. Three models are of value, the cotton tail rabbit papillomavirus (CRPV), bovine papillomavirus (BPV) and the canine oral papillomavirus (COPV) [for review, see (23) ]. In addition to its natural host, the wild cotton tail rabbit, CRPV infects domestic rabbits although the viral life cycle is usually incomplete in this species. CRPV only infects haired skin and, in view of the extreme tissue tropism of the pvs, it is possible that the CRPV/domestic rabbit model may not accurately reflect the immunobiology of the mucosal viruses.
BPV-4 is a mucosatrophic virus infecting the oropharynx and oesophagus of cattle. However there are difficulties in monitoring the incidence and progression of lesions in these sites and the specialised husbandry requirements of such large animals precludes their use by most experimenters.
The canine oral papillomavirus (COPV) is good model for mucosatrophic pv infection [for review see (18) ]. COPV infects domestic dogs and wild canine species on the oropharyngeal and conjunctival mucosae where it induces warts (and very rarely squamous cell carcinomas (3, 26, 29) ). The development of lesions is highly reproducible both in terms of wart area and time providing clean readouts for vaccine efficacy. There is a good range of canine immunological reagents and assays of both humoral and cell mediated response can be undertaken, providing fundamental data on the mode of action of the vaccine preparations.
In natural papillomavirus infections in the cow, rabbit and dog antibodies to the major capsid protein L1 are protective (4, 14, 25) ; prophylactic vaccine development has therefore focussed on this antigen. Prophylactic immunity can be induced in these animal models, with whole virus preparations (2) or virus like particles (VLPs) (6, 12, 25 ) generated by self assembly of recombinant L1 protein expressed in eukaryotic vectors; denatured L1 does not offer prophylactic protection in the dog (25) and rabbit (14) . DNA once dried has long term stability over a wide temperature range and recombinant expression vectors encoding the DNA sequence of the antigen are able to induce long term cellular and humoral immunity (7, 19) without the need to purify protein products and produce VLPs. DNA can be delivered intra-muscularly (i.m.) by needle injection (27) or intra-cutaneously (i.c.) (20, 21) using the gene gun for particle-mediated DNA delivery (PMDD). Each route induces both cellular and humoral immunity but PMDD provides a strong cellular and humoral response with 100-1000 fold lower DNA doses than the needle injection route (9, 21 nitrogen. Sections were cut on a cryostat, stained routinely with haematoxylin and eosin, and examined by light microscopy. Once the optimal pressure had been established using the cadaver material, the β-galactosidase reporter construct (pCMV-SPORT-βgal) was used in vivo on one beagle dog to check that the delivery protocol resulted in protein expression in the target tissues. After PMDD to the oral mucosa 6mm punch biopsies were taken at 2 and 9 days for detection of β-galactosidase activity.
Detection of β-galactosidase Activity. Tissues were embedded in optimal cutting temperature compound (OCT, BDH) and frozen in isopentane (BDH) cooled to its freezing point in liquid nitrogen. Frozen tissue was stored at -70 °C ready for cryostat sectioning. 10 µm sections were cut and air dried for at least 30 min. The sections were fixed by immersion in 100% ethanol for 2 min then washed in PBS (3 x 3 min.). The slides were immersed in development solution (70 ml PBS, 10 ml 50mM potassium ferricyanide, 10 ml 50mM potassium ferrocyanide, 4 ml 50mM magnesium chloride, 1 ml 1 % sodium deoxycholate, 2 ml 1% Nonidet P-40. 100 mg x-gal powder was dissolved in 2.5 ml dimethylsulphoxide and added just prior to use) at 37 °C for 2 hours. After washing in PBS (3 x 3 min.), the sections were counterstained in Carazzi's haematoxylin (45 seconds) and mounted in aquamount (Gurr). Negative control sections were from normal canine oral mucosa. rings at the fluid/air interface of the culture medium (500 ml GMEM, with the following added by filter sterilisation: 50 ml foetal bovine serum, 5 ml kanamycin (10 mg/ml), 125 µl amphotericin (5 mg/ml), 500 µl cholera toxin (10 -7 M in serum free medium), 250 µl hydrocortisone (1 mg/ml)). The explants were incubated at 37°C, 5% CO 2 . Medium was refreshed every other day, and biopsies were harvested at 1, 3
Detection of in vitro
and 5 days after transfection. As negative controls, non-transfected tissues were cultured in a similar manner.
COPV DNA was detected by in situ hybridisation and COPV L1 protein was detected by immunohistochemistry as previously described (17) (figure 2).
RNA-RNA in situ hybridisation. Digoxygenin labelled riboprobes were prepared as per manufacturers instructions (Roche Diagnostics, Welwyn-GardenCity). Sections on Vectabond-coated slides (Vector laboratories) were dewaxed and rehydrated washed in PBS (2 x 3 min.) and encircled with a silicone pen (DAKO).
The tissues were fixed in 4% paraformaldehyde with 5mM MgCl 2 in PBS for 5 min.
and re-washed in PBS (2 x 3 min.). After digestion in RNAse-free DNAse (15 U/ml) in 2 x SSC for 1 hour at 37 °C in a humid chamber, the sections were washed in PBS (2 x 3 min.) and digested in Protease K (50 µg/ml in Protease K buffer (0.02M Tris hours and a final wash, the plates were developed using an s-phenylene diamine/peroxide substrate in urea buffer (Sigmafast). Colour development was stopped with 20% sulphuric acid and absorbance levels were read at 490nm using a Molecular Devices plate reader.
Isolation of Peripheral Blood Monocytes (PBMC). 10 ml of canine blood was collected into a universal tube containing 100 µl of 100 mg/ml EDTA and diluted with an equal volume of PBS/EDTA (5.38 ml 0.5M Disodium EDTA in 500 ml 1x PBS). 5 ml of diluted blood was layered on top of 5 ml Ficol-Paque (Pharmacia), than centrifuged in a Sorvall (RC-3B) for 45 min at room temperature, 1,500 g, with the brake turned off. Cells from the interface were collected using a 1. challenge did not co-localise with the sites of immunisation. COPV virus was isolated and purified as described previously (17) .
RESULTS
β-Galactosidase Expression Study. In order to determine the optimum pressure for delivery of gold particles into oral and cutaneous sites in the dog, a fresh canine cadaver was used to test different pressures for gold delivery. Cryostat sections from biopsies taken immediately after the procedure showed that a pressure of 400 psi delivered gold particles into the epidermis, reaching the basal layer (data not shown). This pressure was used subsequently in the in vivo work. To establish whether the delivery technique and construct expression system were effective in vivo, a β-galactosidase reporter construct (pCMV-SPORT-βgal) was delivered by PMDD into canine oral mucosa. β-galactosidase activity was detected in small amounts in the superficial layers of the oral mucosal epithelium in biopsies taken two days later, but not in those taken nine days later or in negative control samples. Gold particles were seen in the epidermis at two days, but not nine days, although occasional gold particles remained in the underlying dermis at nine days (figure 1). (numbers 1-6) however, showed no significant COPV L1 antibody response to COPV prior to viral challenge ( figure 5 ). This lack of anti-COPV antibody was associated with a susceptibility to subsequent viral challenge, as illustrated by papilloma formation at the challenge sites.
DNA Vaccination and Viral
Animals 9, 10, 11 and 12 in the L1 vaccine group all showed a similar response; a specific anti-L1 antibody response was elicited by the vaccinations. The circulating antibody levels induced by the vaccine were then reduced after the animals were challenged, remaining stable at this lower level. Animal number 7 showed a moderate level antibody response to vaccination, which was maintained for approximately one month after challenge. Thereafter, the antibody titre rose to a maximum by 8 weeks post challenge and was maintained for at least a further month.
The final animal dog 8 showed only a low anti-L1 antibody response to virus, this low response was maintained throughout the experiment did not alter on challenge and the animal was protected ( figure 6 ). showed only a minimal proliferative response before challenge (figure 8). The average S.I. for the L1 group was a significant proliferation response of 1.9. After challenge all six animals had a response to COPV with an average S.I. of 2.2.
DISCUSSION
The work described above shows that COPV L1 specific, humoral, prophylactic immunity can be elicited by intra cutaneous and mucosal immunisation with the COPV L1 gene on a CMV driven plasmid. The vaccination protocol used resulted in complete protection for all animals at 60 of 60 sites challenged with purified COPV. A total dose of less than 30µg of DNA in total, delivered in 3 doses of 9µg was sufficient to protect individuals against viral challenge. This vaccine dose elicited not only anti L1 IgG antibodies recognising COPV virions but also a specific T lymphoproliferative response to COPV virions.
In the experiments described in this report, sera from all animals were analysed against whole virus rather than COPV VLPs. This provided a cleaner readout in ELISA and ensured that the antibody response detected was directed predominantly against conformational epitopes found on native virions. The anti-L1 titres generated were modest, a phenomenon observed also with COPV L1 VLP vaccines (25) . 
